Clinical Trial Update: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira [Phase 3]

View source ↗

Summary

Phase 3 study comparing the biosimilar GP2017 to Humira in plaque psoriasis completed; results posted in 2017. The results indicate equivalent efficacy and simi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• GP2017 (adalimumab)
• Humira (adalimumab)

Snippet

Sponsor: Sandoz | Conditions: Plaque Type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2017-04-07